

KINDRED HEALTHCARE, INC  
Form 8-K  
April 12, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**  
**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 11, 2006

---

**KINDRED HEALTHCARE, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>001-14057</b> (Commission File Number) <b>680 South Fourth Street</b>  <b>Louisville, Kentucky</b> (Address of principal executive offices)	<b>61-1323993</b> (IRS Employer Identification No.)
	<b>40202-2412</b> (Zip Code)	

Registrant's telephone number, including area code: (502) 596-7300

Not Applicable

(Former name or former address, if changed since last report)

## Edgar Filing: KINDRED HEALTHCARE, INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On April 11, 2006, Kindred Healthcare, Inc. (the Company) announced that it has authorized the voluntary delisting of its Series A Warrants to Purchase Common Stock and its Series B Warrants to Purchase Common Stock from the Nasdaq National Market effective at the close of trading on April 17, 2006. Both the Series A Warrants and Series B Warrants will expire by their terms on April 20, 2006. The delisting of the Series A Warrants and Series B Warrants will permit pending trades through the Nasdaq National Market to settle prior to the April 20 expiration date in accordance with the standard T+3 trade settlement period.

**Item 7.01. Regulation FD Disclosure.**

Incorporated by reference is a press release issued by the Company on April 11, 2006, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of such section.

**Item 9.01.**

(c) Exhibits

Exhibit 99.1 Press release dated April 11, 2006.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

Date: April 11, 2006

By: /s/ Richard A. Lechleiter  
Richard A. Lechleiter  
Executive Vice President and  
Chief Financial Officer